Lifestance Health Group (LFST) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for June 3, 2025, to be held virtually for stockholders of record as of April 11, 2025.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request by May 23, 2025.
Voting matters and shareholder proposals
Election of three director nominees to serve until the 2028 annual meeting: Teresa DeLuca, M.D., Katherine Wood, and Eric Palmer.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2025.
Advisory vote on the compensation of named executive officers.
Provision for transacting other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends a vote in favor of all three main proposals: director elections, auditor ratification, and executive compensation approval.
Latest events from Lifestance Health Group
- 2025 delivered strong growth and margins, with 2026 guidance projecting further expansion and $100M buyback.LFST
Q4 202525 Feb 2026 - Q2 revenue up 20%, Adjusted EBITDA doubled, and guidance raised for 2024.LFST
Q2 20242 Feb 2026 - Margin expansion and strategic M&A set to drive growth beyond 2025, despite near-term payer headwinds.LFST
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Hybrid care, operational discipline, and payer wins fuel growth and margin expansion.LFST
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 19% to $312.7M, net loss narrowed, and guidance raised for key metrics.LFST
Q3 202416 Jan 2026 - Revenue up 19% and Adjusted EBITDA more than doubled, with strong 2025 growth outlook.LFST
Q4 202419 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve executive pay amid strong 2024 results.LFST
Proxy Filing1 Dec 2025 - Q2 2025 revenue up 11%, net loss narrowed, and record Free Cash Flow drove raised guidance.LFST
Q2 202523 Nov 2025 - Q1 2025 saw 11% revenue growth, margin gains, and first positive net income as a public company.LFST
Q1 202518 Nov 2025